Suppr超能文献

埃塞俄比亚提格雷地区二线抗逆转录病毒治疗的结果及预测因素

Second-Line Antiretroviral Treatment Outcomes and Predictors in Tigray Region, Ethiopia.

作者信息

Gidey Kidu, Mache Abadi, Hailu Berhane Yohannes, Asgedom Solomon Weldegebreal, Tassew Segen Gebremeskel, Nirayo Yirga Legesse

机构信息

Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia.

出版信息

Infect Drug Resist. 2023 Jul 27;16:4903-4912. doi: 10.2147/IDR.S419348. eCollection 2023.

Abstract

INTRODUCTION

Ethiopia has one of the highest HIV burdens in sub-Saharan Africa. Despite the fact that second-line antiretroviral therapy (ART) has been available for more than ten years, studies on its effectiveness are scarce.

OBJECTIVE

To assess treatment outcomes and predictors of unfavorable outcomes in HIV patients receiving second-line ART at Ayder Comprehensive Specialized Hospital and Mekelle Hospital.

MATERIALS AND METHODS

An institution-based retrospective cohort study was conducted in two hospitals in Tigray Region, Ethiopia. We evaluated 192 patients aged ≥15 years who were switched to second-line from November 2009 to May 2020 after failure of first-line ART. The primary outcome was the time from the initiation of second-line ART to the occurrence of unfavorable treatment outcomes (treatment failure, death, and loss to follow-up). We performed Kaplan-Meier survival estimates to calculate the cumulative incidence rates of unfavorable outcomes.

RESULTS

The mean age (SD) at the initiation of second-line ART was 39 (10.03) years, and the median CD4 cell count was 121 cells/microL. During a median follow-up of 4.6 years, 24 (12.5%) patients had died, 11 (5.7%) patients were lost to follow up, and 47 (24,4%) patients were experienced treatment failure. The incidence rates for unfavorable outcomes were 7.8 per 100 patients/years. Predictors for unfavorable outcomes were body mass index (BMI) <18.5 (adjusted hazard ratio [aHR] = 2.51, 95% confidence interval (CI): 1.27-4.95) and CD4 counts ≤100 cells/microL (aHR = 1.74, 95% CI: 1.09-2.79). Despite the failure of second-line ART, none of the patients received third-line ART.

CONCLUSION

The incidence rate of unfavorable treatment outcomes for second-line ART was found to be high. A low BMI and a low baseline CD4 count were significant predictors of unfavourable outcomes and should be given special consideration in HIV care. A third-line ART regimen should also be considered for people who have failed second-line ART.

摘要

引言

埃塞俄比亚是撒哈拉以南非洲地区艾滋病毒负担最高的国家之一。尽管二线抗逆转录病毒疗法(ART)已经应用了十多年,但关于其有效性的研究却很少。

目的

评估在阿伊德综合专科医院和梅克内尔医院接受二线抗逆转录病毒治疗的艾滋病毒患者的治疗结果及不良结果的预测因素。

材料与方法

在埃塞俄比亚提格雷地区的两家医院开展了一项基于机构的回顾性队列研究。我们评估了192名年龄≥15岁的患者,这些患者在一线抗逆转录病毒治疗失败后于2009年11月至2020年5月期间转而接受二线治疗。主要结局是从开始二线抗逆转录病毒治疗到出现不良治疗结局(治疗失败、死亡和失访)的时间。我们采用Kaplan-Meier生存估计法来计算不良结局的累积发生率。

结果

开始二线抗逆转录病毒治疗时的平均年龄(标准差)为39(10.03)岁,CD4细胞计数中位数为121个/微升。在中位随访4.6年期间,24名(12.5%)患者死亡,11名(5.7%)患者失访,47名(24.4%)患者经历了治疗失败。不良结局的发生率为每100患者年7.8例。不良结局的预测因素为体重指数(BMI)<18.5(调整后风险比[aHR]=2.5, 95%置信区间[CI]:1.27-4.95)和CD4计数≤100个/微升(aHR=1.74, 95% CI:1.09-2.79)。尽管二线抗逆转录病毒治疗失败,但没有患者接受三线治疗。

结论

发现二线抗逆转录病毒治疗的不良治疗结局发生率很高。低BMI和低基线CD4计数是不良结局的重要预测因素,在艾滋病毒护理中应给予特别考虑。对于二线抗逆转录病毒治疗失败的患者,也应考虑三线抗逆转录病毒治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ad17/10390760/b0f354dd163c/IDR-16-4903-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验